Treatment of vaginitis caused by Candida glabrata: Use of topical boric acid and flucytosine

Jack D. Sobel, Walter Chaim, Viji Nagappan, Deborah Leaman

    Research output: Contribution to journalArticlepeer-review

    145 Scopus citations


    OBJECTIVE: The purpose of this study was to review the treatment outcome and safety of topical therapy with boric acid and flucytosine in women with Candida glabrata vaginitis. STUDY DESIGN: This was a retrospective review of case records of 141 women with positive vaginal cultures of C glabrata at two sites, Wayne State University School of Medicine and Ben Gurion University. RESULTS: The boric acid regimen, 600 mg daily for 2 to 3 weeks, achieved clinical and mycologic success in 47 of 73 symptomatic women (64%) in Detroit and 27 of 38 symptomatic women (71%) in Beer Sheba. No advantage was observed in extending therapy for 14 to 21 days. Topical flucytosine cream administered nightly for 14 days was associated with a successful outcome in 27 of 30 of women (90%) whose condition had failed to respond to boric acid and azole therapy. Local side effects were uncommon with both regimens. CONCLUSIONS: Topical boric acid and flucytosine are useful additions to therapy for women with azolerefractory C glabrata vaginitis.

    Original languageEnglish
    Pages (from-to)1297-1300
    Number of pages4
    JournalAmerican Journal of Obstetrics and Gynecology
    Issue number5
    StatePublished - 1 Jan 2003


    • Boric acid
    • Candida glabrata
    • Flucytosine
    • Vaginitis

    ASJC Scopus subject areas

    • Obstetrics and Gynecology


    Dive into the research topics of 'Treatment of vaginitis caused by Candida glabrata: Use of topical boric acid and flucytosine'. Together they form a unique fingerprint.

    Cite this